SCHEMBL6072055

SCHEMBL6072055

COC(=O)c1ccc(C2=NC(C)(C)Cc3cc(OC)c4c(c32)CC(C)(C)O4)cc1NC(=O)c1cccc(NC(C)=O)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 1/20 0.36
POLB P06746 4/20 0.36
ABCB1 P08183 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
CLK1 P49759 1/20 0.35
PARP1 P09874 1/20 0.35
IDO1 P14902 1/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPT P10636 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072675 0.94 IDO1 (0.39) KDM4EALDH1A1POLBCLK1PARP1
SCHEMBL6071856 0.93 CREBBP (0.39) LMNAALDH1A1POLBABCB1ABCG2
SCHEMBL6072085 0.90 POLB (0.42) ALDH1A1POLBTSHRMAPK1HSD17B10
SCHEMBL6072219 0.87 SMN1; SMN2 (0.39) LMNAALDH1A1POLBCLK1TSHR
SCHEMBL5784127 0.86 POLB (0.40) ALDH1A1POLBTSHRMAPK1MAPT
SCHEMBL5784867 0.84 BRAF (0.40) POLBIDO1TSHRMAPK1MAPT
SCHEMBL6071949 0.83 HDAC1 (0.38) KDM4EALDH1A1GAAPOLBTSHR
SCHEMBL5786798 0.83 BRAF (0.39) POLBIDO1KMT2ANPC1RAB9A
SCHEMBL5781645 0.83 IDO1 (0.37) LMNAKDM4EALDH1A1GAAPOLB
SCHEMBL5783550 0.83 PDE4A (0.44) LMNAMAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A LMNA 2455/4885KDM4E 358/4885ALDH1A1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.